Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × hypericin × Clear all
NCT05872854 2026-02-09

RW-HPN-MF-01

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
10 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT05380635 2023-06-07

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Soligenix

Phase 2 Completed
9 enrolled 9 charts
Lymphoid

Mycosis Fungoides

Data powered by HemOnc (CC BY 4.0) Colophon âš¡